Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bungyo Rate Increases to 42.8% in June
October 15, 2001
- Cooperation for Immediate PMS Urged by SD Director
October 15, 2001
- WORLD NEWS IN BRIEF
October 15, 2001
- Korosho to Reduce Number of Hospital Beds by Shortening Hospital Stay
October 15, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 15, 2001
- REGULATORY NEWS IN BRIEF
October 15, 2001
- Etiology of Alzheimer Disease Should Be Clarified by 2013
October 15, 2001
- Mr Nagayama Calls For Drug Prices Proportional to Value
October 15, 2001
- Inhalant Steroids Are Effective for Asthma: Yomiuri, GSK Forum
October 15, 2001
- Bayer to File NDA for Vardenafil by Year-end in Japan
October 15, 2001
- Sysmex Aims at \72 Bil. Sales, 7.5% ROE in FY2004
October 15, 2001
- Ohmori, Sanuki, Baikado Tie Up to Cover Entire Shikoku Market
October 15, 2001
- Toshiba Develops 0.25mm Multi-slice CT Technology
October 15, 2001
- Sales Up for 23 Generic Houses, Down for 22: EMA Survey
October 15, 2001
- Guidant Japan to Introduce New Defibrillator
October 15, 2001
- BUSINESS NEWS IN BRIEF -1-
October 15, 2001
- Instrumentarium Imaging to Launch New X-ray Mammograph
October 15, 2001
- Mitsubishi Pharma Revises Business Forecasts Upward
October 15, 2001
- Fujisawa Revises Business Forecasts Upward
October 15, 2001
- Laerdal Medical to Launch Patient Simulator SimMan
October 15, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…